+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Companion Diagnostics (CDx) Market Report 2024-2034

  • PDF Icon

    Report

  • 307 Pages
  • January 2024
  • Region: Global
  • Visiongain
  • ID: 5930706
Description Jump to:
Overall world revenue for Companion Diagnostics (CDx) Market, 2024 to 2034 in terms of value the market will surpass US$6,500 million in 2024. The publisher predicts strong revenue growth through to 2034. This report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Companion Diagnostics (CDx) Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will be useful for companies that want to expand into different industries or their existing operations in a new region.

Technological Improvements in the CDx Market

The market for CDx is expanding thanks in large part to technological developments. Better, more sensitive, and more focused CDx tests are coming from these developments. Important technical developments in CDx include the following:-
  • Next-generation sequencing (NGS): Entire tumour genomes can be sequenced using NGS, a high-throughput sequencing technology. This data can be used to pinpoint genetic mutations that particular medications can target.
  • Liquid biopsy: A less intrusive procedure that can identify cancer cells and other indicators in the circulation is liquid biopsy. This test can be used to track the course of cancer and the effectiveness of treatment and is less intrusive than conventional tissue biopsies.
  • AI (artificial intelligence): AI is being used to create computer algorithms capable of analysing enormous amounts of CDx data. This information can be utilised to spot patterns and forecast patient outcomes.
These technological improvements are having a significant impact on the CDx industry and are projected to fuel market expansion in the coming years. CDx tests are getting more accurate, sensitive, and inexpensive as a result of these improvements, and they are playing an increasingly essential role in personalised medicine.

In 2023, a number of significant businesses plan to make significant investments in companion diagnostics. Here are few instances:-
  • Roche: With a strong emphasis on cancer, Roche is a prominent player in the companion diagnostics (CDx) market. The business has created a number of complementary diagnostics for its targeted cancer treatments, including Zelboraf and Herceptin.
  • Another significant participant in the companion diagnostics business is Abbott Laboratories. The Clariscan companion diagnostic test from the company assists in forecasting a patient's reaction to the chemotherapy medication irinotecan.
  • Thermo Fisher Scientific: This top supplier of tools and supplies for companion diagnostic testing is Thermo Fisher Scientific. Several firms are developing companion diagnostic tests using the company's Ion Torrent NGS platform.
Hence, these improvements and new product introductions highlight the CDx market's dynamic nature and its potential to revolutionise cancer therapy by providing precision medicine.

High Capital Investment and Low Cost-benefit Ratio Likely to Challenge Industry Growth

These specialised tests require significant capital expenditure to design and validate. Companion diagnostics, in contrast to more general diagnostic instruments, serve a specific and narrower population. This indicates that the market may not be as large as expected, which would make it difficult to recover the high expenses associated with R&D and obtaining necessary permits. These tests also frequently need for advanced infrastructure and technologies, which raises the cost even further.

The development and validation of these specialised tests necessitates substantial capital commitment. Companion diagnostics, as opposed to broader diagnostic instruments, target a smaller, more specific group. As a result, the market size may be limited, making it difficult to recoup the significant expenditures of research, development, and regulatory approvals. Furthermore, these examinations frequently necessitate expensive technology and infrastructure, which increases the budgetary load.

However, calculating the cost-benefit ratio might be difficult. Companion diagnostics have the potential to improve treatment efficacy and reduce waste by ensuring that the right patients receive the proper treatment. This can result in cost reductions for healthcare systems as well as better patient outcomes. However, realising these benefits is contingent on a number of circumstances, including the prevalence of the targeted group, the efficacy of the companion medication, and the cost of the test itself.

When the target population is small or the diagnostic cost is high, the cost-benefit ratio may be skewed to the negative. Manufacturers may be discouraged from investing in companion diagnostics, even if they provide great therapeutic value.

What Questions Should You Ask Before Buying a Market Research Report?:

  • How is the companion diagnostics (CDx) market evolving?
  • What is driving and restraining companion diagnostics (CDx) market?
  • How will each companion diagnostics (CDx) submarket segment grow over the forecast period, and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each companion diagnostics submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading companion diagnostics (CDx) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034, and which geographical region will lead the market in 2034?
  • Who are the leading players, and what are their prospects over the forecast period?
  • What are the companion diagnostics (CDx) projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of companion diagnostics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialization to further scale companion diagnostics (CDx) market?
  • Where is the companion diagnostics (CDx) market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Companion Diagnostics (CDx) Market today, and over the next 10 years::

  • The 307-page report provides 100 tables and 170 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Companion Diagnostics (CDx) Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects:

  • In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Companion Diagnostics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product & Services:

  • Assays, Kits & Reagents
  • Software & Services

Technology:

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Other Technologies

Indication:

  • Cancer
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other Indications

End-users:

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations (CROs)
  • Other End-users
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and the U.S., China, U.K., India, and Brazil leading national markets:

North America:

  • U.S.
  • Canada

Europe:

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific:

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America:

  • Brazil
  • Mexico
  • Rest of Latin America

MEA:

  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Companion Diagnostics (CDx) Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading Companies profiled in the report:

  • Abbott
  • Agilent Technologies, Inc.
  • Almac Group
  • bioMerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

How will the Companion Diagnostics (CDx) Market, 2024 to 2034 report help you?

In summary, the 300+ page report provides you with the following knowledge:-
  • Revenue forecasts to 2034 for Companion Diagnostics (CDx) Market, 2024 to 2034, with forecasts for product & services, technology, indication, and end-users each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 16 key national markets – See forecasts for the Companion Diagnostics (CDx) Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for Abbott, Agilent Technologies, Inc., Almac Group, bioMerieux, Danaher Corporation, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Myriad Genetics, Inc,, QIAGEN, Sysmex Corporation, and Thermo Fisher Scientific Inc. and other major companies involved in the Companion Diagnostics (CDx) Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how the report could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Companion Diagnostics (CDx) Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Companion Diagnostics (CDx) Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Rate of Chronic Illnesses
3.2.1.2 Technological Improvements in the CDx Market
3.2.1.3 Increasing Public Awareness of Personalised Medicine
3.2.1.4 Growing Need for Targeted Therapy
3.2.1.5 Rising Importance of Personalized Medicine
3.2.1.6 Increasing Global Incidence of Cancer
3.2.1.7 Growing Application Areas of Companion Diagnostics
3.2.2 Market Restraining Factors
3.2.2.1 Serious Issues and Substantial Medical Costs
3.2.2.2 Creating and Approving CDx Tests is a Challenging and Intricate Process.
3.2.2.3 High Capital Investment and Low Cost-benefit Ratio
3.2.2.4 Uncertain Reimbursement Scenario in Different Regions
3.2.2.5 High Cost of Immunotherapy Treatment
3.2.3 Market Opportunities
3.2.3.1 Creating New CDx Tests for Novel Targeted Medicines
3.2.3.2 Favourable Government Policies
3.2.3.3 Expansion into New Geographic Markets
3.2.3.4 Increasing Demand for Next-Generation Sequencing in CDx
3.2.3.5 Growing Significance of Companion Diagnostics in Drug Development
3.2.3.6 Higher Number of Clinical Trials
3.3 COVID-19 Impact Analysis
3.4 Porter Analysis
3.5 PEST Analysis
4 Companion Diagnostics (CDx) Market Analysis by Product & Services
4.1 Key Findings
4.2 Product & Services Segment: Market Attractiveness Index
4.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
4.4 Assays, Kits & Reagents
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Software & Services
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
5 Companion Diagnostics (CDx) Market Analysis by Indication
5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
5.4 Cancer
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Infectious Disease
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Cardiovascular Diseases
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Neurological Diseases
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Other Indications
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)
6 Companion Diagnostics (CDx) Market Analysis by Technology
6.1 Key Findings
6.2 Technology Segment: Market Attractiveness Index
6.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
6.4 Polymerase Chain Reaction (PCR)
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Next-Generation Sequencing (NGS)
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 In Situ Hybridization (ISH)
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Immunohistochemistry (IHC)
6.7.1 Market Size by Region, 2024-2034 (US$ Million)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Other Technologies
6.8.1 Market Size by Region, 2024-2034 (US$ Million)
6.8.2 Market Share by Region, 2024 & 2034 (%)
7 Companion Diagnostics (CDx) Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
7.4 Pharmaceutical & Biopharmaceutical Companies
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Reference Laboratories
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Contract Research Organizations (CROs)
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Other End-users
7.7.1 Market Size by Region, 2024-2034 (US$ Million)
7.7.2 Market Share by Region, 2024 & 2034 (%)
8 Companion Diagnostics (CDx) Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Companion Diagnostics (CDx) Market Analysis
9.1 Key Findings
9.2 North America Companion Diagnostics (CDx) Market Attractiveness Index
9.3 North America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
9.5 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
9.6 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
9.7 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
9.8 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
9.9 U.S. Companion Diagnostics (CDx) Market Analysis
9.10 Canada Companion Diagnostics (CDx) Market Analysis
10 Europe Companion Diagnostics (CDx) Market Analysis
10.1 Key Findings
10.2 Europe Companion Diagnostics (CDx) Market Attractiveness Index
10.3 Europe Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
10.5 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
10.6 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
10.7 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
10.8 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
10.9 Germany Companion Diagnostics (CDx) Market Analysis
10.10 UK Companion Diagnostics (CDx) Market Analysis
10.11 France Companion Diagnostics (CDx) Market Analysis
10.12 Italy Companion Diagnostics (CDx) Market Analysis
10.13 Spain Companion Diagnostics (CDx) Market Analysis
10.14 Rest of Europe Companion Diagnostics (CDx) Market Analysis
11 Asia Pacific Companion Diagnostics (CDx) Market Analysis
11.1 Key Findings
11.2 Asia Pacific Companion Diagnostics (CDx) Market Attractiveness Index
11.3 Asia Pacific Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
11.5 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
11.6 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
11.7 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
11.8 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
11.9 China Companion Diagnostics (CDx) Market Analysis
11.10 Japan Companion Diagnostics (CDx) Market Analysis
11.11 India Companion Diagnostics (CDx) Market Analysis
11.12 Australia Companion Diagnostics (CDx) Market Analysis
11.13 South Korea Companion Diagnostics (CDx) Market Analysis
11.14 Rest of Asia Pacific Companion Diagnostics (CDx) Market Analysis
12 Latin America Companion Diagnostics (CDx) Market Analysis
12.1 Key Findings
12.2 Latin America Companion Diagnostics (CDx) Market Attractiveness Index
12.3 Latin America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
12.5 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
12.6 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
12.7 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
12.8 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
12.9 Brazil Companion Diagnostics (CDx) Market Analysis
12.10 Mexico Companion Diagnostics (CDx) Market Analysis
12.11 Rest of Latin America Companion Diagnostics (CDx) Market Analysis
13 MEA Companion Diagnostics (CDx) Market Analysis
13.1 Key Findings
13.2 MEA Companion Diagnostics (CDx) Market Attractiveness Index
13.3 MEA Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
13.5 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
13.6 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
13.7 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
13.8 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
13.9 South Africa Companion Diagnostics (CDx) Market Analysis
13.10 GCC Companion Diagnostics (CDx) Market Analysis
13.11 Rest of MEA Companion Diagnostics (CDx) Market Analysis
14 Company Profiles
14.1 Strategic Outlook
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2017-2022
14.2.3.2 R&D, 2017-2022
14.2.3.3 Regional Market Shares, 2022
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Agilent Technologies, Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2017-2022
14.3.3.2 R&D, 2017-2022
14.3.3.3 Regional Market Shares, 2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 QIAGEN
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2017-2022
14.4.3.2 R&D, 2017-2022
14.4.3.3 Regional Market Shares, 2022
14.4.4 Product Benchmarking
14.5 Thermo Fisher Scientific Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2017-2022
14.5.3.2 Regional Market Shares, 2022
14.5.4 Product Benchmarking
14.6 Abbott
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2022
14.6.3.2 R&D, 2017-2022
14.6.3.3 Regional Market Shares, 2022
14.6.4 Product Benchmarking
14.7 Almac Group
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.7.4 Strategic Outlook
14.8 Danaher Corporation
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2017-2022
14.8.3.2 Regional Market Shares, 2022
14.8.4 Product Benchmarking
14.9 Illumina, Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2017-2022
14.9.3.2 R&D, 2017-2022
14.9.3.3 Regional Market Shares, 2022
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 bioMerieux
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2017-2022
14.10.3.2 Regional Market Shares, 2022
14.10.4 Product Benchmarking
14.11 Myriad Genetics, Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2017-2022
14.11.3.2 R&D, 2017-2022
14.11.3.3 Regional Market Shares, 2022
14.11.4 Product Benchmarking
14.12 Sysmex Corporation
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2017-2022
14.12.3.2 R&D, 2017-2022
14.12.3.3 Regional Market Shares, 2022
14.12.4 Product Benchmarking
14.13 Guardant Health
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2017-2022
14.13.3.2 R&D, 2017-2022
14.13.3.3 Regional Market Shares, 2022
14.13.4 Product Benchmarking
15 Conclusion and Recommendations
15.1 Concluding Remarks
15.2 Recommendations for Market Players
List of Tables
Table 1 Companion Diagnostics (CDx) Market Snapshot, 2024 & 2034 (US$ Million, AGR %)
Table 2 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “V” Shaped Recovery
Table 3 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “U” Shaped Recovery
Table 4 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “W” Shaped Recovery
Table 5 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “L” Shaped Recovery
Table 6 Companion Diagnostic Market Forecast by Product & Services, 2024-2034 (US$ Million, CAGR%)
Table 7 Assays, Kits & Reagents Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 8 Software & Services Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 9 Companion Diagnostic Market Forecast by Indication, 2024-2034 (US$ Million, CAGR%)
Table 10 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 11 Infectious Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 12 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 13 Neurological Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 14 Other Indications Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 15 Companion Diagnostic Market Forecast by Technology, 2024-2034 (US$ Million, CAGR%)
Table 16 PCR Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 17 Next-Generation Sequencing (NGS) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 18 In Situ Hybridization (ISH) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 19 Immunohistochemistry (IHC) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 20 Other Technologies Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 21 Companion Diagnostic Market Forecast by End-users, 2024-2034 (US$ Million, CAGR%)
Table 22 Pharmaceutical & Biopharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 23 Reference Laboratories Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 Contract Research Organizations (CROs) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 25 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 26 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Table 27 North America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 28 North America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 29 North America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 30 North America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 31 North America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 32 U.S. Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 33 Canada Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 34 Europe Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 35 Europe Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 36 Europe Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 37 Europe Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 38 Europe Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 39 Germany Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 40 UK Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 41 France Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 42 Italy Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 43 Spain Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 44 Rest of Europe Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 45 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 46 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 47 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 48 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 49 Asia Pacific Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 50 China Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 51 Japan Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 52 India Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 53 Australia Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 54 South Korea Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 55 Rest of Asia Pacific Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 56 Latin America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 57 Latin America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 58 Latin America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 59 Latin America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 60 Latin America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 61 Brazil Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 62 Mexico Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 63 Rest of Latin America Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 64 MEA Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 65 MEA Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 66 MEA Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 67 MEA Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 68 MEA Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 69 South Africa Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 70 GCC Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 71 Rest of MEA Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 72 Strategic Outlook
Table 73 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 74 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 75 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 76 Agilent Technologies, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Agilent Technologies, Inc.: Product Benchmarking
Table 78 Agilent Technologies, Inc.: Strategic Outlook
Table 79 QIAGEN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 QIAGEN: Product Benchmarking
Table 81 Thermo Fisher Scientific: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Thermo Fisher Scientific.: Product Benchmarking
Table 83 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Abbott: Product Benchmarking
Table 85 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Almac Group: Product Benchmarking
Table 87 Almac Group: Strategic Outlook
Table 88 Danaher Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Danaher Corporation: Product Benchmarking
Table 90 Illumina: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Illumina: Product Benchmarking
Table 92 Illumina: Strategic Outlook
Table 93 bioMerieux: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Biomurieux: Product Benchmarking
Table 95 Myriad Genetics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 MYRIAD GENETICS, INC.: Product Benchmarking
Table 97 Sysmex Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Sysmex Corporation: Product Benchmarking
Table 99 Guardant Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 GUARDANT HEALTH: Product Benchmarking
List of Figures
Figure 1 Companion Diagnostics (CDx) Market Segmentation
Figure 2 Companion Diagnostics (CDx) Market by Technology: Market Attractiveness Index
Figure 3 Companion Diagnostics (CDx) Market by Indication: Market Attractiveness Index
Figure 4 Companion Diagnostics (CDx) Market by Product & Services: Market Attractiveness Index
Figure 5 Companion Diagnostics (CDx) Market by End-users: Market Attractiveness Index
Figure 6 Companion Diagnostics (CDx) Market Attractiveness Index by Region
Figure 7 Companion Diagnostics (CDx) Market: Market Dynamics
Figure 8 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 9 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 10 Companion Diagnostic Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 11 Companion Diagnostic Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 12 PEST Analysis of Companion Diagnostic Market
Figure 13 Companion Diagnostics (CDx) Market by Product & Services: Market Attractiveness Index
Figure 14 Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 15 Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024, 2029, 2034 (%)
Figure 16 Assays, Kits & Reagents Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 17 Assays, Kits & Reagents Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 18 Software & Services Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 19 Software & Services Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Companion Diagnostics (CDx) Market by Indication: Market Attractiveness Index
Figure 21 Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 22 Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 23 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 24 Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Infectious Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 26 Infectious Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 28 Cardiovascular Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Neurological Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 30 Neurological Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Other Indications Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 32 Other Indications Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Companion Diagnostics (CDx) Market by Technology: Market Attractiveness Index
Figure 34 Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 35 Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024, 2029, 2034 (%)
Figure 36 Polymerase Chain Reaction (PCR) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 37 Polymerase Chain Reaction (PCR) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Next-Generation Sequencing (NGS) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 39 Next-Generation Sequencing (NGS) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 40 In Situ Hybridization (ISH) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 41 In Situ Hybridization (ISH) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Immunohistochemistry (IHC) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 43 Immunohistochemistry (IHC) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 44 Other Technologies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 45 Other Technologies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Companion Diagnostics (CDx) Market by End-users: Market Attractiveness Index
Figure 47 Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 48 Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 49 Pharmaceutical & Biopharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 50 Pharmaceutical & Biopharmaceutical Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 51 Reference Laboratories Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 52 Reference Laboratories Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 53 Contract Research Organizations (CROs) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 54 Contract Research Organizations (CROs) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 57 Companion Diagnostics (CDx) Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 58 Companion Diagnostics (CDx) Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 59 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 60 North America Companion Diagnostics (CDx) Market Attractiveness Index
Figure 61 North America Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 62 North America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 63 North America Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 64 North America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 65 North America Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 66 North America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 67 North America Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 68 North America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 69 North America Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 70 North America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 71 North America Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 72 U.S. Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 73 Canada Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 74 Europe Companion Diagnostics (CDx) Market Attractiveness Index
Figure 75 Europe Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 76 Europe Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 77 Europe Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 78 Europe Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 79 Europe Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 80 Europe Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 81 Europe Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 82 Europe Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 83 Europe Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 84 Europe Companion Diagnostics (CDx) Market Forecast by End-user, 2024-2034 (US$ Million, AGR %)
Figure 85 Europe Companion Diagnostics (CDx) Market Share Forecast by End-user, 2024 & 2034 (%)
Figure 86 Germany Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 UK Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 88 France Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 89 Italy Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 90 Spain Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 91 Rest of Europe Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 92 Asia Pacific Companion Diagnostics (CDx) Market Attractiveness Index
Figure 93 Asia Pacific Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 94 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 95 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 96 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 97 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 98 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 99 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 100 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 101 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 102 Asia Pacific Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 103 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 104 China Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 105 Japan Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 106 India Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 107 Australia Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 108 South Korea Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 109 Rest of Asia Pacific Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 110 Latin America Companion Diagnostics (CDx) Market Attractiveness Index
Figure 111 Latin America Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 112 Latin America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 113 Latin America Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 114 Latin America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 115 Latin America Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 116 Latin America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 117 Latin America Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 118 Latin America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 119 Latin America Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 120 Latin America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 121 Latin America Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 122 Brazil Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 123 Mexico Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 124 Rest of Latin America Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 125 MEA Companion Diagnostics (CDx) Market Attractiveness Index
Figure 126 MEA Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 127 MEA Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 128 MEA Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 129 MEA Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 130 MEA Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 131 MEA Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 132 MEA Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 133 MEA Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 134 MEA Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 135 MEA Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 136 MEA Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 137 South Africa Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 138 GCC Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 139 Rest of MEA Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 140 F. Hoffmann-La Roche Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 141 F. Hoffmann-La Roche Ltd: R&D, 2017-2022 (US$ Million, AGR%)
Figure 142 F. Hoffmann-La Roche Ltd: Regional Market Shares, 2022
Figure 143 Agilent Technologies, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 144 Agilent Technologies, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 145 Agilent Technologies, Inc.: Regional Market Shares, 2022
Figure 146 QIAGEN: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 147 QIAGEN: R&D, 2017-2022 (US$ Million, AGR%)
Figure 148 QIAGEN: Regional Market Shares, 2022
Figure 149 Thermo Fisher Scientific: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 150 Thermo Fisher Scientific.: Regional Market Shares, 2022
Figure 151 Abbott: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 152 Abbott: R&D, 2017-2022 (US$ Million, AGR%)
Figure 153 Abbott: Regional Market Shares, 2022
Figure 154 Danaher Corporation: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 155 Danaher Corporation: Regional Market Shares, 2022
Figure 156 Illumina: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 157 Illumina: R&D, 2017-2022 (US$ Million, AGR%)
Figure 158 Illumina: Regional Market Shares, 2022
Figure 159 bioMerieux: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 160 bioMerieux: Regional Market Shares, 2022
Figure 161 Myriad Genetics, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 162 Myriad Genetics, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 163 Myriad Genetics, Inc.: Regional Market Shares, 2022
Figure 164 Sysmex Corp: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 165 Sysmex Corp: R&D, 2017-2022 (US$ Million, AGR%)
Figure 166 Sysmex Corp: Regional Market Shares, 2022
Figure 167 Guardant Health: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 168 Guardant Health: R&D, 2017-2022 (US$ Million, AGR%)
Figure 169 GUARDANT HEALTH, INC: Regional Market Shares, 2022

Companies Mentioned

  • Abbott
  • Agilent Technologies, Inc.
  • Almac Group
  • bioMerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Akoya Biosciences
  • Alcimed
  • AstraZeneca plc
  • Becton, Dickinson and Company
  • Cytek Biosciences
  • Genentech
  • GenMark Diagnostics
  • Laboratory Corporation of America Holdings
  • Merck Group
  • TScan Therapeutics
  • Polish National Health Fund
  • Spanish National Cancer Research Centre
  • The Korean Food and Drug Administration (KFDA)
  • The Medicines and Healthcare Products Regulatory Agency
  • The National Healthcare Security Administration (NHSA)
  • The National Medical devices Administration (NMPA)
  • World Health Organization (WHO)

Related Topics

Related Reports

Companion Diagnostics (CDx) Market - Forecasts from 2024 to 2029 - Product Image

Companion Diagnostics (CDx) Market - Forecasts from 2024 to 2029

  • Report
  • 121 Pages
  • Global
From
Companion Diagnostics: Technologies and Markets 2023-2028 - Product Image

Companion Diagnostics: Technologies and Markets 2023-2028

  • Report
  • 121 Pages
  • Global
From
Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Companion Diagnostic Market - The Future of Diagnostics by Application, Technology and Funding with Executive and Consultant Guides - Product Image

Companion Diagnostic Market - The Future of Diagnostics by Application, Technology and Funding with Executive and Consultant Guides

  • Report
  • 546 Pages
  • Global
From
Companion Diagnostic Market Analysis & Forecast to 2024-2034 - Product Image

Companion Diagnostic Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.